ArticleCancer research2012

Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.

Zoë Weaver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.